Shire PLC (SHPG) Sees Large Decrease in Short Interest

Shire PLC (NASDAQ:SHPG) was the recipient of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 2,421,141 shares, a drop of 34.8% from the January 12th total of 3,712,240 shares. Based on an average daily volume of 1,775,924 shares, the short-interest ratio is presently 1.4 days. Currently, 0.8% of the shares of the company are sold short.

Hedge funds have recently added to or reduced their stakes in the company. Seizert Capital Partners LLC increased its stake in shares of Shire by 13.3% during the third quarter. Seizert Capital Partners LLC now owns 10,786 shares of the biopharmaceutical company’s stock worth $1,652,000 after purchasing an additional 1,267 shares in the last quarter. Fisher Asset Management LLC increased its stake in shares of Shire by 2.9% during the third quarter. Fisher Asset Management LLC now owns 57,419 shares of the biopharmaceutical company’s stock worth $8,793,000 after purchasing an additional 1,619 shares in the last quarter. Morningstar Investment Services LLC increased its stake in shares of Shire by 53.0% during the third quarter. Morningstar Investment Services LLC now owns 25,882 shares of the biopharmaceutical company’s stock worth $3,964,000 after purchasing an additional 8,969 shares in the last quarter. Trillium Asset Management LLC increased its stake in shares of Shire by 2.3% during the third quarter. Trillium Asset Management LLC now owns 49,083 shares of the biopharmaceutical company’s stock worth $7,517,000 after purchasing an additional 1,082 shares in the last quarter. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Shire during the third quarter worth about $4,338,000. 20.31% of the stock is owned by institutional investors and hedge funds.

Shire (SHPG) opened at $127.43 on Monday. The firm has a market cap of $38,700.00, a price-to-earnings ratio of 24.00, a price-to-earnings-growth ratio of 0.68 and a beta of 1.41. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. Shire has a fifty-two week low of $123.73 and a fifty-two week high of $192.15.

Shire (NASDAQ:SHPG) last released its earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.37 EPS for the quarter, missing analysts’ consensus estimates of $3.86 by ($0.49). Shire had a return on equity of 14.41% and a net margin of 10.95%. equities research analysts expect that Shire will post 15 EPS for the current fiscal year.

Several research analysts recently issued reports on the stock. Piper Jaffray Companies reissued a “hold” rating on shares of Shire in a report on Wednesday, January 3rd. Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Liberum Capital reissued a “hold” rating on shares of Shire in a report on Wednesday, December 20th. Cowen set a $225.00 target price on shares of Shire and gave the stock a “buy” rating in a report on Friday, January 5th. Finally, ValuEngine cut shares of Shire from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. Shire has an average rating of “Hold” and an average target price of $212.50.

WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/02/12/shire-plc-shpg-sees-large-decrease-in-short-interest.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply